Mindfulness-Based Cognitive Therapy (MBCT) and Cognitive Behavioral Therapy (CBT) for Depression in Diabetes Patients

University Medical Center Groningen (UMCG)

Status

Completed

Conditions

Depressive Symptoms

Treatments

Behavioral: Mindfulness-Based Cognitive Therapy (MBCT)

Behavioral: Cognitive Behavioral Therapy (CBT)

Study type

Interventional

Funder types

Other

Identifiers

NCT01630512

METIS

Details and patient eligibility

About

The purpose of this study is to determine whether mindfulness-based cognitive therapy (MBCT)and cognitive behavioral therapy (CBT)are effective in reducing depressive symptoms in patients with diabetes.

Full description

Depression is a common co-morbidity of diabetes, negatively affecting physical performance, glycemic control, adherence to medication, and dietary, and exercise recommendations. Modalities of psychotherapy like cognitive behavioral therapy (CBT) and mindfulness-based cognitive therapy (MBCT) can reduce depressive symptoms in patients with medical conditions. However, proper designed randomized trials assessing and comparing effectiveness of these psychological interventions are rare.

This longitudinal study aims to investigate the effectiveness of CBT and MBCT in reducing depressive symptoms in diabetes patients. Furthermore, potential moderators and mediators of treatment effect will be explored, as well as the role of common factors and treatment integrity.

Enrollment

94 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diabetes mellitus Type 1 or 2 for at least three months prior to inclusion
Written informed consent
Age ≥ 18 and ≤ 70
Depressive symptoms as assessed by BDI-II score ≥ 14 (cut-off score indicating the presence of at least mild symptoms of depression)

Exclusion criteria

Not being able to read and write Dutch
Severe (psychiatric) co-morbidity
Acute suicidal ideations or behavior
Pregnancy
Receiving an alternative psychological treatment during or less than two months prior to starting the participation in the study

Using an antidepressant drug during participation in the present study is allowed, on condition that a patient has been on stable medication regimen for at least two months prior to inclusion in the study, and that no new treatment with an antidepressant is initiated during the course of the study